Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage.

Parkinson Study Group.

Clin Neuropharmacol. 2007 Mar-Apr;30(2):72-85.

PMID:
17414939
2.

Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

Dooley M, Markham A.

Drugs Aging. 1998 Jun;12(6):495-514. Review.

PMID:
9638397
3.

Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002259. Review.

PMID:
10908539
4.

Pramipexole extended release in Parkinson's disease.

Hametner EM, Seppi K, Poewe W.

Expert Rev Neurother. 2011 Sep;11(9):1229-34. doi: 10.1586/ern.11.122. Review.

PMID:
21864066
5.

Pramipexole for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002261. Review.

PMID:
10908540
6.

Pramipexole for the treatment of early Parkinson's disease.

Perez-Lloret S, Rey MV, Ratti L, Rascol O.

Expert Rev Neurother. 2011 Jul;11(7):925-35. doi: 10.1586/ern.11.75. Review. Erratum in: Expert Rev Neurother. 2011 Aug;11(8):1220. Perez Lloret, Santiago [corrected to Perez-Lloret, Santiago].

PMID:
21721909
7.
8.

[Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].

Kohno Y, Takeuchi S.

Nihon Yakurigaku Zasshi. 2004 Jun;123(6):429-40. Review. Japanese.

PMID:
15170083
9.

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Fahn S; Parkinson Study Group.

J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.

PMID:
16222436
10.

Levodopa in the treatment of Parkinson's disease.

Fahn S.

J Neural Transm Suppl. 2006;(71):1-15. Review.

PMID:
17447410
11.
12.

Pramipexole extended-release: a review of its use in patients with Parkinson's disease.

Frampton JE.

Drugs. 2014 Dec;74(18):2175-90. doi: 10.1007/s40265-014-0322-5. Review.

PMID:
25385556
13.

Role of pramipexole in the management of Parkinson's disease.

Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G.

CNS Drugs. 2010 Oct;24(10):829-41. doi: 10.2165/11585090-000000000-00000. Review.

PMID:
20839895
14.

Pramipexole extended release: in Parkinson's disease.

Chwieduk CM, Curran MP.

CNS Drugs. 2010 Apr;24(4):327-36. doi: 10.2165/11204570-000000000-00000. Review.

PMID:
20297857
15.

Treatment of depressive symptoms in Parkinson's disease.

Barone P.

Eur J Neurol. 2011 Mar;18 Suppl 1:11-5. doi: 10.1111/j.1468-1331.2010.03325.x. Review.

PMID:
21255198
16.

Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.

Zagmutt FJ, Tarrants ML.

Int J Neurosci. 2012 Jul;122(7):345-53. doi: 10.3109/00207454.2012.660586. Epub 2012 Mar 23. Review.

PMID:
22304415
17.

[Pramipexole and Parkinson's disease, an update].

Martínez-Corral M, Kulisevsky J.

Rev Neurol. 2008 Jan 1-15;46(1):49-52. Review. Spanish.

18.

Pramipexole in the treatment of Parkinson's disease: new developments.

Möller JC, Oertel WH.

Expert Rev Neurother. 2005 Sep;5(5):581-6. Review.

PMID:
16162081
19.

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease.

Hametner EM, Seppi K, Poewe W.

Clin Interv Aging. 2012;7:83-8. doi: 10.2147/CIA.S11829. Epub 2012 Mar 15. Review.

20.

[A current view on dopamine receptor agonists in the treatment of Parkinson's disease].

Titova NV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(9):76-83. doi: 10.17116/jnevro20151159176-83. Review. Russian.

PMID:
26525820

Supplemental Content

Support Center